

A

- Abacavir, 171
- Abbreviations, 187–189
- Acetic acid otic solution, 120
- Acute osteomyelitis, 1–2, 93–95
 - antibiotics and, 93–94
 - background information, 1
 - clinical findings, potential complications, 93
 - diagnosis, 2
 - diagnostic tests, 2
 - medications history, 1
 - microbiologic etiology, 93
 - oral therapy, 95
 - physical examination, 1–2
 - self-assessment questions, 2
 - vancomycin intolerance, 94–95
 - tyramine-containing foods and, 94
- Acute otitis externa, 25–26, 119–120
 - background information, 25
 - diagnosis, 26, 119
 - diagnostic tests, 26
 - medication record, 26
 - otic solution contact techniques, 120
 - pathogens, 119
 - physical examination, 25–26
 - risk factors, 119
 - ruptured tympanic membrane, 120
 - self-assessment questions, 26
 - topical antibiotic adverse effects, 120
 - topical antibiotics, 119–120
 - treatment plan, 119
- Acute otitis media, 23–24, 117–118
 - antimicrobial resistance, 117–118
 - background information, 23
 - diagnosis, 24
 - diagnostic tests, 24
 - immunizations, 118

medication record, 24
 organisms causing, 117
 physical examination, 23–24
 risk factors, 118
 self-assessment questions, 24
 TMP/SMX, 117, 118

Acyclovir, 181, 182

Advisory Committee on Immunization Practices, 112, 113

Amantadines, 129

American Academy of Pediatrics, 108, 118

American Thoracic Society, 170

Aminoglycosides, 135

Amoxicillin, 108, 117, 118, 123, 136, 140, 161, 178

Amoxicillin/clavulanate, 118

Amphotericin B, 176

Ampicillin, 66, 138

Ampicillin/sulbactam, 125, 135

Antibiogram, 66, 75

Antibiotic lock therapy, 142

Antibiotic resistance, 45–47, 141–143. *See* also specific cases

Antibiotics, 93–94, 122

Antimicrobial stewardship team, 126, 168

Antipseudomonal agents, 135

Antipyrine/benzocaine otic solution, 120

Antiseptic, 119

Atovaquone, oral, 169

Azithromycin, 108, 111, 115, 122, 136, 178, 180

B

Bacteremia, gram negative, 55–56, 151–152
 aminoglycosides, 152
 antifungal treatment, 152
 background information, 55
 diagnosis, 56
 diagnostic tests, 56
 empiric therapy, 151
 gentamicin dosage, 152
 imipenem with tobramycin, 151
 likely cause of infection, 151
 medication record, 56
 physical examination, 56
 self-assessment questions, 56
 splenectomy, 151

Bacteremia, gram positive, 51–53, 149–150
 antimicrobial agents, duration, 149
 background information, 51
 central catheter-related infection prevention, 149
 diagnosis, 52
 diagnostic tests, 52
 infusion rate, 150
 medication record, 52
 methicillin-resistant *Staphylococcus aureus*, 150
 physical examination, 52
 self-assessment questions, 52–53
 vancomycin trough level range, 149–150

Benzathine penicillin G, 115

Beta-lactams, 135, 140

Breastfeeding, 118

Butoconazole, 174

C

Candidiasis. *See* Vulvovaginal candidiasis
 disseminated. *See* Disseminated candidiasis

Carbapenem, 135

Casposungin, 176

Catheter-related bloodstream infection—
 antibiotic resistance, 45–47, 141–143
 antibiotic lock therapy, 142
 aseptic technique, 142–143
 background information, 45
 diagnosis, 46
 diagnostic tests, 46
 mechanism of resistance, 141–142
 medication record, 46
 MRSA strain, 142
 physical examination, 45–46
 prevention strategies, 142–143
 self-assessment questions, 46–47

Cefazolin, 111, 145, 150

Cefazolin with metronidazole, 167

Cefdinir, 118

Cefepime, 100, 101, 168

Cefepime IV, 158

Cefixime, 179

Cefotaxime, 66, 138, 180

Cefoxitin, 167

Cefpodoxime, 118

Ceftaroline, 98, 101, 150

Ceftazidime, 100, 101, 112

Ceftazidime plus gentamicin, 126

Ceftriaxone, 108, 111, 112, 115, 118, 123, 135, 139, 162, 168, 180

Ceftriaxone plus azithromycin, 122, 179

Ceftriaxone with metronidazole, 167

Cefuroxime, 118, 167, 168, 178

Cefuroxime with metronidazole, 167

Cellulitis, 99

Centers for Disease Control and Prevention, 115, 129, 149, 170, 174, 179

Central venous catheters, 149

Cephalexin, 99, 100

Cephalosporin, 112, 118, 122

Chloramphenicol, 112

Ciprofloxacin, 66, 99, 108, 112, 113, 122, 127

Ciprofloxacin plus gentamicin, 126

Ciprofloxacin with metronidazole, 167

Ciprofloxacin/hydrocortisone otic solution, 120

Clarithromycin, 122, 136

Clindamycin, 95, 98, 102, 136, 140, 142, 154

Clindamycin and primaquine, 169, 170

Clostridium difficile. *See* Gastrointestinal infection—*Clostridium difficile*

Clotrimazole, 174

Cockcroft-Gault equation, 150

Community-acquired pneumonia, 27–29, 121–123
 acceptable sputum specimen, 121
 background information, 27–28
 diagnosis, 28, 122
 diagnostic tests, 28
 high resistance to penicillin, 122–123
 IDSA guidelines, 121, 122
 medication record, 28
 physical examination, 28
 preventative strategies for, 123
 resistance risk factors, 123
 self-assessment questions, 28–29
 signs, symptoms of, 121
 treatment regimen, 122

Complicated urinary tract infection—
 geriatric, 61–63, 157–159
 antibiotics, 158
 background information, 61
 cefazolin, 158

diagnosis, 62
 diagnostic tests, 62
 medication record, 62
 pharmacologic and nonpharmacologic measures, 159–160
 physical examination, 61–62
 risk factors, potential pathogens, 157
 self-assessment questions, 62–63
 urinary catheter use, 159
 urosepsis, pyelonephritis duration of therapy, 158

Corticosteroid, 119

Crystalline penicillin G, 115

D

Dalbavain, 95

Dalbavancin, 98

Dapsone and atovaquone, 170

Daptomycin, 94, 95, 98, 101, 111, 149

Darunavir (boosted) and atazanavir, 171

Dexamethasone, 112

Diabetic foot infection, 7–8, 101–102

antimicrobial stewardship team, 102

background information, 7

diagnostic tests, 8, 102

diagnosis, 8

IDSA classification, 101

medication record, 8

microbiologic etiology, 101

MRSA, 102

physical examination, 7–8

self-assessment questions, 8

treatment plan for severe, 101

Diphenoxylate, 108

Disseminated candidiasis, 83–84, 175–176

antifungal agent, 175

Aspergillus species, 176

background information, 83–84

diagnosis, 84

diagnostic tests, 84

fluconazole resistance, 176

low CrCl, 176

medication record, 84

non-*albicans* *Candida*, 176

physical examination, 84

risk factors, 175

self-assessment questions, 84

Dobutamine, 156

Dolutegravir, 171

Doripenem, 167

Doxycycline, 95, 102, 115, 122, 178

E

Eagle effect, 154

Echinocandin, 152, 175, 176

Efavirenz, 172

Elvitegravir, 171

Ertapenem, 100, 167, 168

Erythromycin, 122, 142

Ethambutol with protease inhibitor, 170

Etravirine, 171

F

Famciclovir, 181, 182

Fidaxomicin, 103, 105

Flagyl, 104

Flu. *See* Influenza

Fluconazole, 112, 152, 174, 175, 176

FluMist Quadrivalent, 123

Fluoroquinolones, 104, 122, 135, 158, 164–165

Fluzone, 123

Food and Drug Administration, 171

G

Gastrointestinal infection—*Clostridium difficile*, 9–11, 103–105

asymptomatic conditions, 103–104

background information, 9–10

diagnosis, 10

diagnostic tests, 10

medication record, 10

metronidazole treatment, 104

pharmacologic plan, 103

physical examination, 10

risk factors, 104

self-assessment questions, 10–11

treatment options, 105

vancomycin treatment, 104–105

Gastrointestinal infection—*Shigella*, 13–15, 107–109

adult occurrences, 108

antidiarrheal agents and, 108

antimicrobial agent for, 108

background information, 13–14

bacterial vs. viral infection characteristics, 107

diagnosis, 14

diagnostic tests, 14

medication record, 14

physical examination, 14

poor sanitation, 108

rotavirus in children, 107

self-assessment questions, 14–15

Gemifloxacin, 100

Gemifloxacin plus azithromycin, 180

Genital herpes, 89–90, 181–183

acyclovir treatment goal, 181

background information, 89

chronic suppressive therapy, 181–182

counseling points, 182

diagnosis, 90

diagnostic tests, 90

disseminated neonatal, 182–183

HIV positive, 182

medication record, 90

physical examination, 89–90

self-assessment questions, 90

treatment regimen, 181

Gentamicin, 66, 111, 126–127, 138, 139, 145, 152

Gentamicin with azithromycin, 180

Geriatric complicated urinary tract infection. *See* Complicated urinary tract infection—geriatric

Gonorrhea. *See* *Neisseria gonorrhoea*

Guillain-Barré syndrome, 130

H

Healthcare-associated pneumonia, 39–40, 135–136

Acinetobacter spp., 135

amoxicillin reaction and, 136

background information, 39

combination therapy, 135

diagnosis, 40

diagnostic tests, 40

immunizations, 136

medication record, 40

physical examination, 39–40

postantibiotic effects, 135

self-assessment questions, 40
therapy complications, 135–136

HIV—medication management, 79–80, 171–172
antiretroviral agents and meal, 172
ART, 171
background information, 79
diagnosis, 80
diagnostic tests, 80
efavirenz and vivid dreams, 172
medication record, 80
physical examination, 80
pneumonia prophylaxis, 171
regimen change, 171–172
self-assessment questions, 80
toxoplasmosis prophylaxis, 171
vaccines, 172

HIV—*Pneumocystis jirovecii* pneumonia, 77–78, 169–170
alternative regimens, 169
background information, 77
diagnosis, 78
diagnostic tests, 78
medication record, 78
PCP prophylaxis, 170
physical examination, 78
plasma HIV RNA, 169
ritonavir, 169
self-assessment questions, 78
sulfamethoxazole/trimethoprim treatment, 169
tuberculosis, 170

HPV vaccine, 172

I

Imipenem, 66, 75, 158, 168
Imipenem with tobramycin, 151
Imipenem/cilastatin, 101, 102, 127, 162, 167
Imodium, 103
Infectious Diseases Society of America, 101, 108, 142, 168, 175, 178
Infective endocarditis—*Staphylococcus*, 49–50, 145–147
background information, 49
dental procedure, 146
diagnosis, 50
diagnostic tests, 50
medication record, 50

methicillin-sensitive *Staphylococcus*, 145–146
physical examination, 50
risk factors, 145
self-assessment questions, 50
TEE vs. TTE evaluation, 145

Infective endocarditis—viridans group streptococci, 43–44, 139–140
background information, 43
cephalosporin use, 140
dental procedure, 140
diagnosis, 44, 139
diagnostic tests, 44
Duke criteria, 139
empiric treatment options, 139
medication record, 44
penicillin resistant strain, 140
physical examination, 43
self-assessment questions, 44
vancomycin use, 140

Influenza, 35–36, 129–130
antiviral treatment to shorten duration, 129–130
background information, 35
CDC recommendations, 129
diagnosis, 36
diagnostic tests, 36
inactivated vaccination, 130
live attenuated vaccination, 130
medication record, 36
neuraminidase inhibitors and, 129
physical examination, 35–36
quadrivalent vaccination, 130
self-assessment questions, 36
treatment plan, 129
vaccine, 178

Intra-abdominal, antibiograms and, 167–168
Intra-abdominal, antimicrobial stewardship team, 168
Intra-abdominal, background information, 73
Intra-abdominal infection, 73–74, 167–168
background information, 73
diagnosis, 74
diagnostic tests, 74, 167
fluoroquinolone resistance, 168
medication record, 74
physical examination, 74
self-assessment questions, 76
single vs. combination therapy, 167–168

treatment duration, 168
treatment time frame, 167

Isoniazid with protease inhibitor, 170
Isoniazid, rifampin, pyrazinamide, ethambutol (or streptomycin), 132
Itraconazole, 176
IV vancomycin, 142

J

Jarisch-Herxheimer reaction, 116

L

Levofloxacin, 100, 122, 135, 168
Levofloxacin plus metronidazole, 125, 167–168
Linezolid, 94, 95, 98, 101, 102, 122, 150, 154
Loperamide, 108
Lyme disease, 85–86, 177–178
background information, 85
DEET tick repellent, 178
diagnosis, 86
diagnostic tests, 86, 178
medication record, 86
physical examination, 85–86
risk factors, 177
self-assessment questions, 86
stages, 177
treatment regimen, 178
vaccinations, 178

M

Macrolide antibiotics, 122, 142
Mantoux test, 131
Maraviroc, 171
Meningitis, 17–19, 111–113
anti-infectives for, 111–112
background information, 17–18
chemoprophylaxis and pregnancy, 113
corticosteroids use in, 112
diagnosis, 18
diagnostic tests, 18
likely pathogens in community-acquired, 111
medication record, 18
physical examination, 18
prophylaxis regimen, 112

self-assessment questions, 18–19
vaccination, 113

Meropenem, 111, 126–127, 167

Methicillin-resistant *Staphylococcus aureus* (MRSA), 95, 97–98, 99, 102, 142, 145–146, 150

Metronidazole, 103, 111, 167–168

Miconazole, 174

Minocycline, 98, 102

Moxifloxacin, 100, 122, 167

N

Nafcillin, 150

Nafcillin plus gentamicin, 145

Neisseria gonorrhoea, 87–88, 179–180

- background information, 87–88
- cephalexin reaction, 180
- complications of untreated, 179
- diagnosis, 88
- diagnostic tests, 88
- dual therapy for, 179
- medication record, 88
- physical examination, 88
- pregnancy, 180
- self-assessment questions, 88
- sexual abstinence, 180
- tender joints, arthritic symptoms, 180
- treatment regimen, 179

Neomycin/hydrocortisone/polymyxin B otic solution, 120

Neonatal sepsis, 41–42, 137–138

- antibiotic discontinuation, 138
- background information, 41
- common causes, 137
- diagnosis, 42
- diagnostic tests, 42
- dosage adjustments, 138
- gentamicin, ampicillin mechanisms of action, 138
- medication record, 42
- physical examination, 41–42
- risk factors, 137
- self-assessment questions, 42

Neurosyphilis, 21–22, 115–116

- background information, 21–22
- characteristic findings, 115–116
- diagnosis, 22, 116
- diagnostic tests, 22

drug treatments, 115

FTA-ABS test, 116

Jarisch-Herxheimer reaction, 116

latent, 116

medication record, 22

physical examination, 22

RPR reduction, 116

self-assessment questions, 22

Nitrofurantoin monohydrate/macrocystals, 164, 165

Norepinephrine, 156

NSAID therapy, 116

O

Ofloxacin otic solution, 120

Oritavancin, 95, 98

Oseltamivir, oral, 129

Osteomyelitis, acute. *See* Acute osteomyelitis

Otitis externa, acute. *See* Acute otitis externa

Otitis media, acute. *See* Acute otitis media

Oxacillin, 141, 150

Oxacillin plus gentamicin, 145

P

Pediatric urinary tract infection. *See* Urinary tract infection—pediatric

Penicillin allergy, 118

Penicillin G, 139, 141

Penicillins, 122

Pentamidine, inhaled, 170

Pentamidine, IV, 169

Peramivir, 129

Phenazopyridine, 159

Piperacillin, 100

Piperacillin/tazobactam, 100, 101, 102, 126, 167, 168

Piperacillin/tazobactam plus gentamicin, 125

Pneumonia, community-acquired, 27–29, 121–123

- community-acquired. *See* Community-acquired pneumonia
- healthcare-associated. *See* Healthcare-associated pneumonia
- Pneumocystis jirovecii*. *See* HIV—*Pneumocystis jirovecii* pneumonia
- vaccine, 172
- ventilator-associated. *See* Ventilator-associated pneumonia

Pneumovax, 123

Posaconazole, 176

Pevnar 13 vaccine, 123

Primaxin, 162

Probiotics, 105

Procaine penicillin, 115

Proton pump inhibitor, 104

Pyrazinamide with protease inhibitor, 170

Pyridoxine, 132

Pyridoxine with protease inhibitor, 170

Q

QuantiFERON-TB Gold In-Tube test, 131–132

Quinolones, 125

Quinupristin/dalfopristin, 142

R

Raltegravir, 171

Rapivab, 129

Rifabutin, 170

Rifampin, 95, 112, 113

Ritonavir, 169

Rotavirus, 107

S

Sepsis

- neonatal. *See* Neonatal sepsis
- severe. *See* Severe sepsis

Septic shock, 59–60, 155–156

- antimicrobial stewardship team, 156
- antimicrobial therapy initiation, 155–156
- background information, 59
- combination therapy, 156
- corticosteroids, 155
- crystalloids use, 156
- diagnosis, 60
- diagnostic tests, 60
- fluid replacement, 155, 156
- medication record, 60
- physical examination, 60
- self-assessment questions, 60
- treatment plan, 155
- vasopressor therapy, 155, 156

Severe sepsis, 57–58, 153–154

- antibiotic therapy, 154

background, 57
 clindamycin use, 154
 crystalloids, 154
 diagnosis, 58
 diagnostic tests, 58
 medication record, 58
 myocardial infarction and, 154
 pathophysiology of, 153
 physical examination, 57–58
 red blood cell transfusion, 154
 resuscitation goals, 153–154
 self-assessment questions, 58
 steroids, 153
Sexually Transmitted Diseases Treatment Guidelines, 115
Shigella. See Gastrointestinal infection—*Shigella*
 Skin, soft tissue infection, 4–5, 97–100
 background information, 3–4
 cellulitis, 97
 diagnosis, 4
 diagnostic tests, 4
 foot cut infection treatment, 99–100
 furuncles, carbuncles, abscesses, 97
 infection control procedures, 99
 medication record, 4–5
 MRSA, 97–98
 physical examination, 4
 self-assessment questions, 5
 topical antibiotic therapy, 99
 vancomycin dosing, regimen, 98
 Soft tissue infection. See Skin, soft tissue infection
Staphylococcus. See Infective endocarditis—*Staphylococcus*
Streptococcus pneumoniae, 117–118
 Sulfamethoxazole/trimethoprim, 102, 170

T

Tdap vaccine, 136, 172, 178
 Tedizolid, 94, 95, 98
 Telavancin, 95, 98
 Tenofovir, emtricitabine, rilpivirine, 172
 Terconazole, 174
 Tetracycline, 115
 Tigecycline, 95, 98
 Tioconazole, 174
 TMP/SMX, 66, 117, 118, 162, 164–166

Topical antibiotics, 119, 120
 Transesophageal echocardiogram, 145
 Transthoracic echocardiogram, 145
 Trimethoprim/sulfamethoxazole, 95, 98, 100
 Tuberculosis, 37–38, 131–133
 background information, 37–38
 diagnosis, 38
 diagnostic tests, 38
 elevated liver function tests, 132
 initial treatment plan, 132
 medication record, 38
 positive reaction to skin test, 131
 QuantiFERON-TB Gold In-Tube test, 131–132
 self-assessment questions, 38
 tuberculin screening skin tests, 131, 132–133

U

Uncomplicated urinary tract infection, 69–71, 163–166
 background information, 69
 bacteria associated with, 163–164
 cystitis, 163
 diagnosis, 70
 diagnostic tests, 70, 163
 medication record, 70
 nitrofurantoin monohydrate/macrocrystals, 165
 physical examination, 70
 pregnancy treatment, 165
 recurrent, 164–166
 risk factors, 163
 self-assessment questions, 71
 spermicide-coated condom use, 165–166
 TMP/SMX treatment, 164–166
 voiding after intercourse, 164
 Urinary catheter use, 159, 160
 Urinary tract infection
 complicated geriatric. See Complicated urinary tract infection—geriatric
 uncomplicated. See Uncomplicated urinary tract infection
 Urinary tract infection—pediatric, 65–66, 161–162
 antibiogram, 161–162
 antibiotic susceptibility patterns, 162
 background information, 65
 ceftriaxone resistance likelihood, 162

diagnosis, 66
 diagnostic tests, 66
 folate synthesis enzyme mutations, 161–162
 imipenem/cilastatin avoidance, 162
 medication record, 66
 physical examination, 65
 self-assessment questions, 66–67

V

Valacyclovir, 181, 182
 Vancomycin, 94–95, 98, 103, 111, 112, 125, 135, 139, 140, 146, 149
 Vancomycin plus aztreonam, 101
 Ventilator-associated pneumonia, 31–33, 125–127
 antibiotic resistance risk factors, 126
 background information, 31
 diagnosis, 32
 diagnostic tests, 32
 increased serum creatinine, 126–127
 medication record, 32
 outpatient therapy, 127
 physical examination, 31–32
 self-assessment questions, 32–33
 sputum sample shows *Pseudomonas aeruginosa*, 126
 therapeutic response worsens, 127
 treatment regimens, 125
 Viridans group streptococci. See Infective endocarditis—viridans group streptococci
 Voriconazole, 175, 176
 Vulvovaginal candidiasis, 81–82, 173–174
 background information, 81
 cause, 173
 counseling points, 174
 diagnosis, 81
 diagnostic tests, 81
 drug therapy options, 174
 medication record, 82
 OTC products, 173–174
 physical examination, 81
 self-assessment questions, 82
 signs, symptoms, risk factors, 173

Z

Zanamivir, inhaled, 129